Clinical and biological characteristics of the 19 patients with ECD and hematologic neoplasm
| . | Diagnosis . | Sex . | BRAF . | Age, y . | Mutations . | WHO classification . |
|---|---|---|---|---|---|---|
| 1 | ECD | M | N/A | 69 | ZRSR2 | MDS-EB, subtype MDS-EB-1 |
| 2 | ECD + LCH | F | VE | 66 | NRAS, TET2 | Multiple myeloma, smoldering |
| 3 | ECD | M | VE | 71 | ASXL1, TET2 | MDS–EB, subtype MDS-EB-1 |
| 4 | ECD | M | VE | 66 | ASXL1, CALR, U2AF1 | MPN/ET |
| 5 | ECD+ LCH | M | VE | 62 | JAK2, TET2 | MPN/ET with myelofibrosis |
| 6 | ECD | M | VE | 57 | ASXL1, PHF6, EZH2, TET2, ZRSR2 | AML NOS, subtype AML with maturation |
| 7 | ECD | M | VE | 72 | ASXL1, JAK2, NRAS, TET2, U2AF1 | MDS-multi |
| 8 | ECD | M | VE | 60 | KRAS, NRAS | MDS-EB, subtype MDS-EB-1 |
| 9 | ECD | M | VE | 73 | ASXL1, ZRSR2 | CMML, subtype CMML-1 |
| 10 | ECD + RDD | M | WT | 74 | IDH2, MPL, SRSF2 | CMML, subtype CMML-1 |
| 11 | ECD | M | WT | 65 | ASXL1, CALR | MPN/PMF, overt fibrotic stage |
| 12 | ECD | M | VE | 79 | TET2 | CMML, subtype CMML-1 |
| 13 | ECD | F | WT | 63 | KRAS | CMML, subtype CMML-1 |
| 14 | ECD + LCH | M | VE | 68 | KRAS, NPM1, NRAS, SMC1A, SRSF2, TET2 | AML |
| 15 | ECD | F | VE | 69 | CBL, NRAS, RIT1, SRSF2 TET2 | CMML, subtype CMML-1 |
| 16 | ECD | F | VE | 60 | JAK2, SF3B1 | MPN/ET |
| 17 | ECD | M | WT | 71 | CALR, DNMT3A, SF3B1 | MPN/PMF, overt fibrotic stage |
| 18 | ECD | M | VE | 58 | None | MPN/CML, BCR-ABL1+ |
| 19 | ECD | M | VE | 50 | None | MDS-MLD |
| . | Diagnosis . | Sex . | BRAF . | Age, y . | Mutations . | WHO classification . |
|---|---|---|---|---|---|---|
| 1 | ECD | M | N/A | 69 | ZRSR2 | MDS-EB, subtype MDS-EB-1 |
| 2 | ECD + LCH | F | VE | 66 | NRAS, TET2 | Multiple myeloma, smoldering |
| 3 | ECD | M | VE | 71 | ASXL1, TET2 | MDS–EB, subtype MDS-EB-1 |
| 4 | ECD | M | VE | 66 | ASXL1, CALR, U2AF1 | MPN/ET |
| 5 | ECD+ LCH | M | VE | 62 | JAK2, TET2 | MPN/ET with myelofibrosis |
| 6 | ECD | M | VE | 57 | ASXL1, PHF6, EZH2, TET2, ZRSR2 | AML NOS, subtype AML with maturation |
| 7 | ECD | M | VE | 72 | ASXL1, JAK2, NRAS, TET2, U2AF1 | MDS-multi |
| 8 | ECD | M | VE | 60 | KRAS, NRAS | MDS-EB, subtype MDS-EB-1 |
| 9 | ECD | M | VE | 73 | ASXL1, ZRSR2 | CMML, subtype CMML-1 |
| 10 | ECD + RDD | M | WT | 74 | IDH2, MPL, SRSF2 | CMML, subtype CMML-1 |
| 11 | ECD | M | WT | 65 | ASXL1, CALR | MPN/PMF, overt fibrotic stage |
| 12 | ECD | M | VE | 79 | TET2 | CMML, subtype CMML-1 |
| 13 | ECD | F | WT | 63 | KRAS | CMML, subtype CMML-1 |
| 14 | ECD + LCH | M | VE | 68 | KRAS, NPM1, NRAS, SMC1A, SRSF2, TET2 | AML |
| 15 | ECD | F | VE | 69 | CBL, NRAS, RIT1, SRSF2 TET2 | CMML, subtype CMML-1 |
| 16 | ECD | F | VE | 60 | JAK2, SF3B1 | MPN/ET |
| 17 | ECD | M | WT | 71 | CALR, DNMT3A, SF3B1 | MPN/PMF, overt fibrotic stage |
| 18 | ECD | M | VE | 58 | None | MPN/CML, BCR-ABL1+ |
| 19 | ECD | M | VE | 50 | None | MDS-MLD |
CML, chronic myeloid leukemia; ET, essential thrombocythemia; MDS-1, myelodysplastic syndrome with single-lineage dysplasia; MDS-EB, myelodysplastic syndrome with excess blast; MDS-MLD, multi–myelodysplastic syndrome with multilineage dysplasia; N/A, not available; NOS, not otherwise specified; PMF, primary myelofibrosis; RDD, Destombes-Rosai-Dorfman disease; VE, BRAF with V600E mutation; WT, BRAF wild type (without V600E mutation).